Implantable medical device developer Tepha said today it completed a buy-out of its roylaty obligations with former licensor and parent company Metabolix. Get the rest of the story at our sister site, Medical Design & Outsourcing
Tepha buys its way out of Metabolix bioresorbables deal
Absorbable biomaterial developer Metabolix said it amended its license agreement with medical device company Tepha, forgoing future royalties and providing 2 additional Metabolix production strains and related IP in exchange for a $2 million lump sum. Read the full story at our sister site, Medical Design & Outsourcing.